KR20080064169A - 암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템 - Google Patents

암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템 Download PDF

Info

Publication number
KR20080064169A
KR20080064169A KR1020087011910A KR20087011910A KR20080064169A KR 20080064169 A KR20080064169 A KR 20080064169A KR 1020087011910 A KR1020087011910 A KR 1020087011910A KR 20087011910 A KR20087011910 A KR 20087011910A KR 20080064169 A KR20080064169 A KR 20080064169A
Authority
KR
South Korea
Prior art keywords
cationic
imaging
administration
complex
imaging agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087011910A
Other languages
English (en)
Korean (ko)
Inventor
에스터 에이치. 장
카트린 에프. 피롤로
Original Assignee
조지타운 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조지타운 유니버시티 filed Critical 조지타운 유니버시티
Publication of KR20080064169A publication Critical patent/KR20080064169A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087011910A 2005-10-20 2006-10-20 암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템 Ceased KR20080064169A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72830305P 2005-10-20 2005-10-20
US60/728,303 2005-10-20

Publications (1)

Publication Number Publication Date
KR20080064169A true KR20080064169A (ko) 2008-07-08

Family

ID=37963345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011910A Ceased KR20080064169A (ko) 2005-10-20 2006-10-20 암의 초기 ｍｒｉ 검출을 개선하기 위한 종양-표적화나노전달 시스템

Country Status (7)

Country Link
JP (1) JP5478886B2 (https=)
KR (1) KR20080064169A (https=)
CN (1) CN101351225B (https=)
AU (1) AU2006304790B2 (https=)
CA (1) CA2638899C (https=)
IL (1) IL190773A (https=)
WO (1) WO2007047981A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2427390C2 (ru) * 2009-06-08 2011-08-27 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН Способ неинвазивного качественного и количественного определения магнитоуправляемых нанопрепаратов и оценки их функций в реальном времени у экспериментальных животных

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2692546C (en) * 2007-07-09 2018-03-13 Esther H. Chang Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
CN111808084A (zh) * 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
CN102078624B (zh) * 2010-12-23 2012-07-25 华东理工大学 一种高效载钆脂质体制剂及其制备方法
WO2013031619A1 (ja) * 2011-08-26 2013-03-07 学校法人藤田学園 抗ヒトトランスフェリン受容体抗体を含む画像用腫瘍診断剤
EP2711000B1 (en) * 2012-09-19 2019-04-03 Georgetown University Targeted Liposomes
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2901616A1 (en) * 2013-03-14 2014-10-02 Georgetown University Treatment for exposure to nerve agent
EP3790533A1 (en) * 2018-05-08 2021-03-17 University of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
EP3962521A1 (en) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
CN117883382B (zh) * 2023-11-27 2025-02-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971692B1 (de) * 1997-03-07 2003-03-05 Max-Delbrück-Centrum Für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
JP4799736B2 (ja) * 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
PL366025A1 (pl) * 2000-05-03 2005-01-24 Munich Biotech Ag Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach
WO2003084386A2 (en) * 2002-04-03 2003-10-16 See Jackie R Methods for ultrasonic imaging and treating diseased tissues
JP2006517032A (ja) * 2003-01-28 2006-07-13 ジョージタウン・ユニバーシティ ある種の癌治療の有効性を評価するための方法
DK1633327T3 (da) * 2003-06-04 2010-11-15 Univ Georgetown Fremgangsmåde til forbedring af stabilitet og opbevaringslevetid af liposomkomplekser
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
JP2005170807A (ja) * 2003-12-09 2005-06-30 Fuji Photo Film Co Ltd 抗体を含むリポソーム

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2427390C2 (ru) * 2009-06-08 2011-08-27 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН Способ неинвазивного качественного и количественного определения магнитоуправляемых нанопрепаратов и оценки их функций в реальном времени у экспериментальных животных

Also Published As

Publication number Publication date
CN101351225A (zh) 2009-01-21
CA2638899A1 (en) 2007-04-26
IL190773A (en) 2012-06-28
WO2007047981A3 (en) 2007-10-25
AU2006304790A1 (en) 2007-04-26
CN101351225B (zh) 2013-09-25
WO2007047981A2 (en) 2007-04-26
CA2638899C (en) 2016-01-05
JP5478886B2 (ja) 2014-04-23
AU2006304790B2 (en) 2013-06-27
HK1129063A1 (en) 2009-11-20
JP2009512712A (ja) 2009-03-26
IL190773A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
US20140178296A1 (en) Tumor-targeted nanodelivery systems to improve early mri detection of cancer
ElBayoumi et al. Current trends in liposome research
IL190773A (en) Antibody or antibody fragment-targeted cationic immunolysome complex and methods of preparing the same
Schnyder et al. Drug transport to brain with targeted liposomes
Mulder et al. Lipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging
US9801943B2 (en) Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry
Mulder et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets
CN1960707B (zh) 用于治疗和/或诊断用途的脂质集合体
Torchilin Multifunctional pharmaceutical nanocarriers: development of the concept
CN103251562B (zh) 改良脂质体复合物的稳定性和保存期的方法
US20130243867A1 (en) Micelle compositions and methods for their use
EP4479095B1 (en) Stealth-stabilized lipo-polyamino acids
JP2004535407A (ja) 標的化多価高分子
Juul et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
Li et al. Smart liposomes for drug delivery
EP3402484B1 (en) Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer
US12377166B2 (en) Iron oxide nanoparticle for targeted chemo-immunotherapy
Khera et al. Highlighting the potential role of exosomes as the targeted nanotherapeutic carrier in metastatic breast cancer
Su et al. In vivo magnetic resonance and fluorescence dual-modality imaging of tumor angiogenesis in rats using GEBP11 peptide targeted magnetic nanoparticles
HK1129063B (en) Tumor-targeted nanodelivery systems to improve early mri detection of cancer
Hirai et al. E‐selectin targeting to visualize tumorsin vivo
Meenu Polymeric and inorganic nanoparticles for cancer treatment and diagnosis
Kozlowska Application of targeted contrast nanoparticles for human multiple myeloma imaging
Yang Developing Heterostructured Nanoparticles for Cancer Therapeutics
HK1188147B (en) Method for improving stability and shelf-life of liposome complexes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111020

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130525

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140328

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130525

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I